Template:Pyelonephritis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) Created page with "==Empiric Therapy for Acute Pyelonephritis <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from ''Clin Infect Dis. 2011;52(5):e103-20.''<ref name="Gupta-2011">{{Cite journal | las..." |
No edit summary |
||
(9 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
==Empiric Therapy for Acute Pyelonephritis <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from ''Clin Infect Dis. 2011;52(5):e103-20.''<ref name="Gupta-2011">{{Cite journal | last1 = Gupta | first1 = K. | last2 = Hooton | first2 = TM. | last3 = Naber | first3 = KG. | last4 = Wullt | first4 = B. | last5 = Colgan | first5 = R. | last6 = Miller | first6 = LG. | last7 = Moran | first7 = GJ. | last8 = Nicolle | first8 = LE. | last9 = Raz | first9 = R. | title = International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. | journal = Clin Infect Dis | volume = 52 | issue = 5 | pages = e103-20 | month = Mar | year = 2011 | doi = 10.1093/cid/ciq257 | PMID = 21292654 }}</ref></SMALL></SMALL></SMALL></SMALL></SMALL>== | ==Empiric Therapy for Acute Pyelonephritis (Outpatient & Inpatient) <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from ''Clin Infect Dis. 2011;52(5):e103-20.''<ref name="Gupta-2011"<ref>{{Cite journal | last1 = Gupta | first1 = K. | last2 = Hooton | first2 = TM. | last3 = Naber | first3 = KG. | last4 = Wullt | first4 = B. | last5 = Colgan | first5 = R. | last6 = Miller | first6 = LG. | last7 = Moran | first7 = GJ. | last8 = Nicolle | first8 = LE. | last9 = Raz | first9 = R. | title = International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. | journal = Clin Infect Dis | volume = 52 | issue = 5 | pages = e103-20 | month = Mar | year = 2011 | doi = 10.1093/cid/ciq257 | PMID = 21292654 }}</ref></SMALL></SMALL></SMALL></SMALL></SMALL>== | ||
{| | {| | ||
Line 59: | Line 58: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen 3''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen 3''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 500 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Ertapenem]] 1 g IV q24h'''''<BR> OR <BR> ▸ '''''[[Doripenem]] 500 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Aztreonam]] 1 g IV q8–12h | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 500 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Ertapenem]] 1 g IV q24h'''''<BR> OR <BR> ▸ '''''[[Doripenem]] 500 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Aztreonam]] 1 g IV q8–12h''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | <SMALL> '''Antibiotics should be administered for at least 10–14 days based on local resistance patterns.''' <BR> '''De-escalation to oral antibiotcs may be considered 24–48 hours after defervescence.''' </SMALL> | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | <SMALL> '''Antibiotics should be administered for at least 10–14 days based on local resistance patterns.''' <BR> '''De-escalation to oral antibiotcs may be considered 24–48 hours after defervescence.''' </SMALL> | ||
|- | |- | ||
|} | |} | ||
|} | |||
|} | |||
==Empiric Therapy for Acute Pyelonephritis (Pregnancy) <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from ''European Association of Urology's Guidelines on Urological Infections'' <ref>{{Cite web | last = | first = | title = http://www.uroweb.org/gls/pdf/18_Urological%20infections_LR.pdf | url =http://www.uroweb.org/gls/pdf/18_Urological%20infections_LR.pdf | publisher = | date = | accessdate = }}</ref></SMALL></SMALL></SMALL></SMALL></SMALL>== | |||
{| style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;" | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center |{{fontcolor|#FFF|Pyelonephritis, Pregnancy}} | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1-2 g IV or IM q24 h'''''<br>OR<br>▸'''''[[Aztreonam]] 1 g IV q8-12 h'''''<br>OR<br>▸ '''''[[Piperacillin-tazobactam]] 3.375-4.5 g IV q6h'''''<br>OR<br>▸ '''''[[Cefepime]] 1 g IV q12 h''''' <BR> OR <BR> ▸ '''''[[Imipenem]]-[[cilastatin]] 500 mg IV q6 h''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | OR | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q6 h''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3-5 mg/kg/day IV in 3 divided doses''''' | |||
|- | |||
|} | |} | ||
|} | |} |
Latest revision as of 20:29, 16 May 2014
Empiric Therapy for Acute Pyelonephritis (Outpatient & Inpatient) Adapted from Clin Infect Dis. 2011;52(5):e103-20.[1]
|
|
Empiric Therapy for Acute Pyelonephritis (Pregnancy) Adapted from European Association of Urology's Guidelines on Urological Infections [2]
|
- ↑ Gupta, K.; Hooton, TM.; Naber, KG.; Wullt, B.; Colgan, R.; Miller, LG.; Moran, GJ.; Nicolle, LE.; Raz, R. (2011). "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases". Clin Infect Dis. 52 (5): e103–20. doi:10.1093/cid/ciq257. PMID 21292654. Unknown parameter
|month=
ignored (help) - ↑ "http://www.uroweb.org/gls/pdf/18_Urological%20infections_LR.pdf" (PDF). External link in
|title=
(help)